Body Weight In Type Research Articles

Analysis methods and case analysis of effect modification (2): effect modification in network Meta-analysis

This paper briefly introduces the characteristics, research significance, and global reporting status of effect modification in network Meta-analysis, demonstrates the heterogeneity caused by effect modification in network Meta-analysis, and emphasizes the importance of exploring effect modification in network Meta-analysis. This paper also summarizes the normalized description and analysis strategies of effect modification in network Meta-analysis. Finally, by the case of "comparison of efficacy of three new hypoglycemic drugs in reducing body weight in type 2 diabetes patients", this paper demonstrates the realization of subgroup analysis and network Meta-regression in exploring effect modification, summarizes the advantages and disadvantages of the two methods, to provide references for future researchers.

Assessing the potential for precision medicine of glucose-lowering drugs in type 2 diabetes mellitus: a meta-regression analysis considering body weight variability from 120 randomized trials

Abstract Background Thus far, randomized controlled trials (RCTs) of glucose-lowering drugs reporting on treatment effects on body weight (BW) as cardiovascular risk factor in type 2 diabetes mellitus have not included precision medicine approaches. However, taking into account treatment response heterogeneity, their potential may be analyzed from published data of RCTs using meta-regression analyses. Both treatment response variation and predictors are required conditions for precision medicine to work. Purpose To assess the potential benefits of precision medicine by quantifying the variation of body weight as patient response to treatment, and to identify predictors which could explain this variation. Methods We used four recent systematic reviews on RCTs comparing pharmacological treatment of type 2 diabetes (included but not limited to sodium-glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists and thiazolidinediones) to placebo. RCTs reporting on BW at baseline and after follow-up to allow for calculation of its logarithmic standard deviation (Log(SD)) in treatment and placebo groups were included. Meta-regression models accounting for treatment means, differing sample sizes, and correlation across treatment from the same trial were used. A separate meta-regression model to evaluate interactions of treatment and individual predictor variables (age, male sex, pre-randomization BW, duration of disease, duration of treatment, year of study and drug class) was applied. Results 120 randomized trials with a total of 43,663 participants were included. The median BW after treatment was 85.2 kg in the placebo groups and 86.2 kg in the therapy groups. A slightly greater treatment response heterogeneity was shown in the therapy groups with a median Log(SD)=2.83 compared to 2.79 from the placebo. After full adjustment in the meta-regression model the difference in BW Log(SD)s was -0.020 (95% CI: -0.063; 0.022) (Figure 1). Scatter plots adjusted for different sample sizes did not show any interaction (i.e. slope divergence) between predictors and the respective treatment (therapy or placebo). Figure 2 demonstrates this using pre-randomization BW as an example. Conclusions We found no major treatment response heterogeneity in RCTs of glucose-lowering drugs reporting on body weight in type 2 diabetes. In addition, none of the considered predictors were able to explain a potential variation in treatment response. The precision medicine approach may thus be of limited value in this setting.

Markers of Glucagon Resistance Improve With Reductions in Hepatic Steatosis and Body Weight in Type 2 Diabetes.

Hyperglucagonemia may develop in type 2 diabetes due to obesity-prone hepatic steatosis (glucagon resistance). Markers of glucagon resistance (including the glucagon-alanine index) improve following diet-induced weight loss, but the partial contribution of lowering hepatic steatosis vs body weight is unknown. This work aimed to investigate the dependency of body weight loss following a reduction in hepatic steatosis on markers of glucagon resistance in type 2 diabetes. A post hoc analysis was conducted from 2 previously published randomized controlled trials. We investigated the effect of weight maintenance (study 1: isocaloric feeding) or weight loss (study 2: hypocaloric feeding), both of which induced reductions in hepatic steatosis, on markers of glucagon sensitivity, including the glucagon-alanine index measured using a validated enzyme-linked immunosorbent assay and metabolomics in 94 individuals (n = 28 in study 1; n = 66 in study 2). Individuals with overweight or obesity with type 2 diabetes were randomly assigned to a 6-week conventional diabetes (CD) or carbohydrate-reduced high-protein (CRHP) diet within both isocaloric and hypocaloric feeding-interventions. By design, weight loss was greater after hypocaloric compared to isocaloric feeding, but both diets caused similar reductions in hepatic steatosis, allowing us to investigate the effect of reducing hepatic steatosis with or without a clinically relevant weight loss on markers of glucagon resistance. The glucagon-alanine index improved following hypocaloric, but not isocaloric, feeding, independently of macronutrient composition. Improvements in glucagon resistance may depend on body weight loss in patients with type 2 diabetes.

Effects of SGLT2 inhibitor administration on blood glucose level and body weight in type 1 diabetes rat model.

The prevalence of diabetes worldwide is increasing and 629 million people are projected to have diabetes by 2045, and the most significant burden of the disease being concentrated in low- and middle-income countries (LMICs). Type 2 diabetes is mainly treated with insulin adjunctive therapies such as metformin to improve insulin sensitivity and sodium-glucose co-transporter 2 (SGLT2) inhibitors to lower blood glucose levels. However, there was limited study on the application of SGLT2 inhibitors on type 1 diabetes, particularly empagliflozin. Therefore, this study aimed to determine the effect of SGLT2 inhibitors on blood glucose levels and body weights in a rat model of type 1 diabetes. To mimic type 1 diabetes, the rats were injected with streptozotocin 60 mg intra-peritoneally. Twenty-four rat models were randomly divided into four groups: normal rat group (negative control), untreated diabetic rat group (positive control), type 1 diabetic rats treated with metformin, and type 1 diabetic rats treated with empagliflozin. Blood glucose levels and body weight were recorded before and after induced with streptozotocin and on weeks 4, 6, 8 and 10 of the treatment with anti-diabetic drugs. This study found that the blood glucose levels before and after treatment significantly decreased in all groups (p<0.05), except in the negative control group. Similar results were observed in body weight of the rats, which all groups experienced weight loss, except the negative control. These results suggested that apart from being used in type 2 diabetes, SGLT2 inhibitors may also be used as a treatment for type 1 diabetes.

Perbaikan Berat Badan Tikus Model Diabetes setelah Pemberian Media Terkondisi Sel Punca Mesensimal (MT-SPM)

This study aims to determine the effect of Mesenchymal Stem Cell Conditioned Medium (MSC-CM) on body weight improvement in type 2 DM rats Rattus Norvegicus, Sprague Dawley strain. Experimental animals were clustered into three groups. The first group as a control (-) that was without STZ and NA induction, the second group as a control (+) was induced by STZ 60 mg/kgBW plus NA 120 mg/kgBW, and the treatment group (P) was induced by STZ and NA then given MT- SPM 0.1 mL/200 g BW intraperitoneally (i.p) once every three days for 30 days. Based on the Independent T-test, a p-value &lt;0.001 or p &lt;0.05 was obtained, so it was concluded that there was a significant difference in body weight in each group. The results showed an increase in body weight in the treatment group (P) compared to the control group (+). Thus, the administration of MSC-CM can improve the condition of type 2 DM by increasing body weight in type 2 DM rat models.

Fabrication and Evaluation of a pH-Responsive Nanocomposite-Based Colonic Delivery System for Improving the Oral Efficacy of Liraglutide.

Oral administration of liraglutide, a protein drug, suffers from low intestinal absorption and instability in the gastrointestinal tract, resulting in low bioavailability. The present study aimed to develop a pH-responsive nanocomposite based-colonic delivery system to improve the oral efficacy of liraglutide. Nanocomplex (AC-Lira) between aminoclay and liraglutide was prepared by a spontaneous self-assembly. After surface charge reversal using citric acid, AC-Lira was coated with poly(methacrylic acid-co-methyl methacrylate) (1:2). The fabricated nanocomplex underwent various in vitro studies to characterize its physicochemical properties, drug release, and cellular transport. In vivo efficacy studies were also conducted using streptozotocin-induced diabetic rats. Both uncoated (AC-Lira) and coated nanocomplex (EAC-Lira) achieved high entrapment efficiency (> 90%) and showed a narrow size distribution. While exhibiting low drug release at pH 1.2 (approximately 30%), EAC-Lira achieved rapid and extensive drug release (~90%) at pH 7.4, displaying pH-dependent drug release. EAC-Lira showed significant size reduction and surface charge reversal during dissolution at pH 7.4, probably due to the removal of the outer coating layer. Furthermore, EAC-Lira was effective at protecting the entrapped proteins against enzymatic degradation. EAC-Lira also increased the membrane transport of liraglutide by 3.5 folds in Caco-2 cells. Owing to enhanced membrane transport and metabolic stability, EAC-Lira improved in vivo efficacy of orally administered liraglutide, significantly reducing blood glucose concentrations, intake of food and water, and body weight in type 2 diabetes rats. These results suggest EAC-Lira is a promising approach to improving the oral bioavailability and efficacy of liraglutide.

The association between the reduction of body weight and new-onset type 2 diabetes remission in middle-aged Japanese men: Population-based Panasonic cohort study 8.

This study aimed to investigate the association between change in body weight (BW) and type 2 diabetes remission in Japanese men with new-onset type 2 diabetes. This study enrolled 1,903 patients with new-onset type 2 diabetes between 2008 and 2013 from a medical health checkup program conducted by the Panasonic Corporation, Osaka, Japan. The baseline was defined as the year of new-onset diabetes. We assessed the type 2 diabetes remission five years after baseline and the association between the change in BW and type 2 diabetes remission using logistic regression analyses. To evaluate the predictive performance of the change in BW, we employed the receiver operating characteristic curves and the area under the receiver operating characteristic (ROC) curve (AUC). The BW loss was associated with type 2 diabetes remission in the participants with a BMI ≥25 kg/m2 but not in the participants with a BMI <25 kg/m2. The odds ratios were 1.96 (95% CI: 1.19-3.29) and 3.72 (95% CI: 2.14-6.59) in the participants with a loss of 5-9.9% and loss of ≥10% for five years, respectively, in the participants with a BMI ≥25 kg/m2 (reference; stable group [0.9% gain to 0.9% loss]). The AUC and cut-off values for the rate of change in BW for type 2 diabetes remission were 0.59 and 5.0%. Body weight loss of ≥5% effectively achieved diabetes remission in Japanese men with a BMI ≥25 kg/m2 and new-onset type 2 diabetes.

The mitigative effect of isorhamnetin against type 2 diabetes via gut microbiota regulation in mice.

In order to demonstrate the effects of isorhamnetin (IH) on the symptoms of type 2 diabetes mellitus (T2DM) and the role of gut microbiota in this process, an T2DM mouse model was established via a high-fat diet and streptozotocin. After 6 weeks of IH intervention and diabetes phenotype monitoring, the mice were dissected. We detected blood indicators and visceral pathology. Contents of the cecum were collected for 16S rRNA sequencing and short chain fatty acid (SCFAs) detection. The results showed that after IH intervention, the body weight of type 2 diabetic mice was gradually stabilized, fasting blood glucose was significantly decreased, and food intake was reduced (P < 0.05). Isorhamnetin significantly increased the level of SCFAs and decreased the levels of blood lipids and inflammatory factors in mice (P < 0.05). 16S rRNA sequencing results showed that Lactobacillus were significantly decreased and Bacteroidales S24-7 group_norank were significantly increased (P < 0.05). Interestingly, gut microbiota was significantly correlated with inflammatory factors, blood lipids, and SCFAs (P < 0.05). Taken together, our data demonstrated that isorhamnetin could improve the diabetic effects in T2DM mice, which might be mediated by gut microbiota.

Dapagliflozin acutely improves kidney function in type 2 diabetes mellitus. The PRECARE study

Dapagliflozin has been demonstrated to improve glycemic control, blood pressure, and body weight in type 2 diabetes mellitus (T2D); indeed, it can also reduce the risk of progression to renal failure, of hospitalization for heart failure and of cardiovascular death. We aim to investigate the acute effect of Dapagliflozin on kidney function in the common clinical practice in T2D. This is a study including 1402 patients with T2D recruited from 11 centers in Lombardia, Italy, who were evaluated at baseline and after 6 months of treatment with Dapagliflozin 10 mg per day. The primary outcome of the study was the change in HbA1c, while the secondary outcomes were modification of weight, BMI, systolic and diastolic pressure, creatinine, eGFR and albuminuria status. After 24 weeks of treatment with Dapagliflozin, a reduction in Hb1Ac was observed (−0.6 ± 1.8%) as well as in BMI (−1.5 ± 5.2 kg/m2). Statistically significant changes were also found for systolic and diastolic blood pressure, cholesterol and triglycerides. Interestingly, a statistically significant acute improvement of kidney function was evident. Our analyses confirm the beneficial effects of dapagliflozin after 6 months of therapy, with improvements of glycemic and lipid profiles, blood pressure, BMI. Finally, an acute positive effect on albuminuria and KIDGO classes was observed during a 6 months treatment with dapagliflozin in patients with T2D.

The Efficacy of Probiotic Supplementations on Glycemic Control, Lipid Profile, Inflammation Biomarkers and Anthropometric Measurements Among Type 2 Diabetes Patients

Background: Probiotics was defined as living organisms by the World Health Organization. These organisms when consumed as in food items or in the form of supplements, can lead to improvements in the health status of the host. Disturbances of intestinal biology contribute to the development of DM. Many trials have shown that the gut microbiome plays a role in the etiology and progression of type 1 and type 2 diabetes and its complications. This trial was designed to identify the effects of multi-species of probiotic supplementation on fasting blood glucose, lipid profile, inflammatory biomarkers, and in type 2 diabetic patients. Participants and methods: 65 type 2 diabetics were divided into 2 groups T (trial) and C (control) or placebo. The T group received daily one capsule of 14 differnt species of probiotic and C group received capsules filled with roasted ground chickpea. Fasting blood glucose, Serum Tumor Necrosis Factor alpha (TNFα) and C Reactive Protein (CRP), HDLC, LDLC, TG, TC levels were measured and anthropometric measurements such as weight, height, waist circumference and BMI were recorded at beginning and the end of the study which lasted for 10 weeks. Results and discussion: In the probiotic group, fasting plasma glucose decreased significantly (P &lt;0.05) compared to the control group, 131.1 ± 10.1 vs 145.7 ± 9.8 (mg/dL). Furthermore, a significant reduction was also apparent TC level in the trial group before and after supplementation (184 ± 31 vs 199 ± 21 ) the difference was significant (P &lt; 0.05). The group which received probiotic also showed significant reduction in TG (P &lt; 0.05) compare to control group ( 128 ± 23 vs 1 1 ± 32 respectively). Also, the LDL value, significantly reduced in the probiotic compared to the control group 137 ± 30 and 149 ± 31 ( P &lt; 0.05). Probiotic supplementation significantly increased HDL 41 ± 13 vs 29.8 ± 12 (P &lt; 0.05). Significant differences (P &lt;0.05) in the serum levels of inflammatory markers at the end of the study were observed. Probiotic supplementation decreases CRP (mg/dL) levels and TNFa (pg/ml) (2.11± 4.3 vs 1.68 ± 3.33 and 2.51 ±2.3 vs 2.31 ± 3.6 respectively).. A significant reduction in TNF-α level was observed. The level was 6.8 5.6 ± at the beginning of the trial and reduced to 5.4± 5.1 whereas in the control group TNF-α levels were 5.6 ± 7.6 and 5.6 ± 7.8 at the beginning and at the end of the study respectively .Probiotics supplementations reduced significantly (P &lt;0.05(BMI of participants in trial group (27.6 ± 5.2 vs 33.8 ± 10.1). Conclusion: The results obtained from this study suggest that probiotic supplementation may have positive effects and can be considered as method to control glucose levels, lipids, inflammatory biomarkers, and reduce body weight in type 2 diabetic patients.

Effects of Porphyra yezoensis extract on hepatic inflammatory factors and oxidative stress in type 1 diabetic mice

To study the effect of Porphyra yezoensis extract on liver inflammation and oxidative stress in type 1 diabetics mice. A total of ninety-one C57 BL/6 J male mice were adaptively fed for two weeks, and twelve C57 BL/6 J male mice were randomly reserved to be included in the blank control group. The rest of the mice were fasted overnight for twelve hours(except water), and they were given 170.00 mg/kg streptozotocin by intraperitoneal injection. Fasting blood glucose in type 1 diabetics mice were greater than or equal to 16.7 mmol/L after seven days, and polydipsia, polyphagia, polyuria and weight loss appeared, which were judged to be the successful model of type 1 diabetes. Forty-eight successfully modeled mice were divided into the model control group, the low dose of Porphyra yezoensis extract group, the medium dose of Porphyra yezoensis extract and high dose of Porphyra yezoensis extract group according to the fasting blood glucose and body weight. The mice in the blank control group and the model group were given the same amount of normal saline. The low-dose, medium-dose, and high-dose intervention groups were separately given the corresponding dose of Porphyra yezoensis extract by intragastric administration for six weeks. The body weight of type 1 diabetic mice, changes in body length, fasting blood glucose, insulin, liver inflammatory factors and oxidative stress indicators and pathological sections of liver and pancreas after the intervention of Porphyra yezoensis extract were observed. The glucose oxidase method was used to determine the fasting blood glucose level of type 1 diabetic mice. The serum insulin content, liver inflammatory factor levels and oxidative stress indicators were detected by the enzyme-linked immunosorbent assay(ELISA). The hematoxylin-eosin staining method was used to observe histopathology of liver and pancreas paraffin sections. The weight of the model control group was significantly lower than that of the blank control group(P&lt;0.05), and the fasting blood glucose value was significantly higher than that of the blank control group(P&lt;0.05). There was no statistical difference. In terms of inflammatory factors, compared with the model control group, low-dose Porphyra yezoensis extract can increase serum insulin levels and reduce liver tumor necrosis factor-α(TNF-α) levels(P&lt;0.05) in T1DM mice, and medium-dose Porphyra yezoensis extract can reduce liver TNF-α level(P&lt;0.05), high-dose Porphyra yezoensis extract can reduce the level of interleukin-1β(IL-1β)(P&lt;0.05). The histopathological conditions of pancreas in different intervention groups were improved compared with the model control group, and the number of β cells increased compared with the model group. In terms of oxidative stress, compared with the model control group, low-dose Porphyra yezoensis extract can significantly reduce the levels of liver alanine aminotransferase(ALT) and malondialdehyde(MDA)(P&lt;0.05), and high-dose Porphyra yezoensis extract can significantly increase the levels of glutathione peroxidase(GSH-Px) and catalase(CAT)(P&lt;0.05). The protective effect of Porphyra yezoensis extract on liver oxidative damage in T1DM mice may be achieved by regulating the activity of CAT and GSH-Px and reducing the content of MDA. In addition, Porphyra yezoensis extract can reduce liver TNF-α and IL-1β levels to improve liver inflammation.

Regulatory network of metformin on adipogenesis determined by combining high-throughput sequencing and GEO database

ABSTRACT Adipose differentiation and excessive lipid accumulation are the important characteristics of obesity. Metformin, as a classic hypoglycaemic drug, has been proved to reduce body weight in type 2 diabetes, the specific mechanism has not been completely clear. A few studies have explored its effect on adipogenesis in vitro, but the existing experimental results are ambiguous. 3T3-L1 preadipocytes were used to explore the effects of metformin on the morphological and physiological changes of lipid droplets during adipogenesis. A high throughput sequencing was used to examine the effects of metformin on the transcriptome of adipogenesis. Considering the inevitable errors among independent experiments, we performed integrated bioinformatics analysis to identify important genes involved in adipogenesis and reveal potential molecular mechanisms. During the process of adipogenesis, metformin visibly relieved the morphological and functional changes. In addition, metformin reverses the expression pattern of genes related to adipogenesis at the transcriptome level. Combining with integrated bioinformatics analyses to further identify the potential targeted genes regulated by metformin during adipogenesis. The present study identified novel changes in the transcriptome of metformin in the process of adipogenesis that might shed light on the underlying mechanism by which metformin impedes the progression of obesity.

Study the Effects of Taurine Oral Supplement used for Type 2 Diabetic Patients on Body Weight; Glycemic Control and Some Bone Mineralization Biochemical Markers

Background: Taurine is sulfur containing semi-essential amino acid that has important roles in many biological processes, but; its effects on glucose homeostasis, weight; growth and bone mineralization were not well defined in human. Objectives: evaluation the effects of oral taurine used for 3 months on bone mineralization biomarker; glycemic control and body weight in type II diabetic patients. Methods: interventional double-blind placebo-controlled study in which 80 patients with type2 diabetes mellitus (age range 45e55) assigned in either control (n ¼ 40) or study (n ¼ 40) group. The last group received 1000 mg capsule of taurine once a -d for three months. Parameters measured were serum calcium, 25(OH) vitamin D and osteocalcin, NTX-1; HbA1C% and Fasting blood glucose before and after 3 months. Results: Taurine led to significant (p < 0.05) rise in osteocalcin and significant lowering in Body weight and BMI and there were no significant changes in Serum Calcium; NTX-1; Vitamin D; HbA1C% and fasting blood glucose; all as compared with control values. Conclusion: 3 months of oral Taurine used in type II diabetic patients may modulate bone mineralization represented by elevation of osteocalcin; and reduction of body weight, but has no significant effect on glycemic control and did not reduce HbA1C%

EFFECT OF THE AQUEOUS EXTRACT OF CLERODENDRUM THOMSONIAE LINN (VERBENACEAE) LEAVES ON TYPE 2 DIABETIC WISTAR RATS INDUCED BY THE MACAPOS1 TYPE DIET AND DEXAMETHASONE

Aim and objective: Clerodendrum thomsoniae leaves are used in Cameroon to manage diabetes and its related disorders. The study aimed at investigating the antidiabetic effect of the aqueous extract on diet and dexamethasone induced diabetic rats. Methods: Young mature leaves of C thomsoniae were dried, finely powdered and submitted to aqueous extraction. The dehydrated extract was tested in rats at 3 doses 312.5, 625 and 1250 mg/kg based on the local use of the plant. The effect of the extract on the fasting blood glucose in normoglycemic rats and MACAPOS 1 type diet induced diabetic rats, using respectively glibenclamide and metformin as positive control groups, were investigated. Results: AECT significantly reduced blood glucose levels in normoglycemic rats (p&lt;0.05) two hours after administration, from 83±2 mg/dL to 57.39±1.7 mg/dL with the dose of 1250 mg/kg. given the highest reduction rate of 30.86%. In normoglycemic rats 30 minutes after oral glucose overload, the maximum reduction rate was observed with glibenclamide 5 mg / kg and calculated at 49.90% followed by 36.39%, for the extract at 1250 mg / kg. After 30 days of repeated oral administration, AECT produced a reduction on blood glucose levels (p&lt;0.05) in type 2 diabetic rats. This reduction in blood sugar was much more expressed with the dose of 1250mg/kg (73.52±0.71 mg/dL) followed by metformin 38mg/kg (70.21±0.89 mg/dL) as the normal control with no significant difference (P &lt; 0.05). Conclusion: These results show that the antidiabetic activity of AECT can be explained by insulin stimulating effect, also give support to the traditional use of this plant. Peer Review History: Received 11 May 2021; Revised 17 June; Accepted 27 June, Available online 15 July 2021 Academic Editor: Dr. Asia Selman Abdullah, Al-Razi university, Department of Pharmacy, Yemen, asia_abdullah65@yahoo.com UJPR follows the most transparent and toughest ‘Advanced OPEN peer review’ system. The identity of the authors and, reviewers will be known to each other. This transparent process will help to eradicate any possible malicious/purposeful interference by any person (publishing staff, reviewer, editor, author, etc) during peer review. As a result of this unique system, all reviewers will get their due recognition and respect, once their names are published in the papers. We expect that, by publishing peer review reports with published papers, will be helpful to many authors for drafting their article according to the specifications. Auhors will remove any error of their article and they will improve their article(s) according to the previous reports displayed with published article(s). The main purpose of it is ‘to improve the quality of a candidate manuscript’. Our reviewers check the ‘strength and weakness of a manuscript honestly’. There will increase in the perfection, and transparency. Received file: Reviewer's Comments: Average Peer review marks at initial stage: 6.5/10 Average Peer review marks at publication stage: 8.0/10 Reviewer(s) detail: Dr. Terhemen Festus Swem, Department of Veterinary Physiology and Biochemistry, College of Veterinary Medicine, Federal University of Agriculture, Makurdi, Benue State, Nigeria, swemfestus422@gmail.com Taha A.I. El Bassossy, Medicinal and Aromatic Plants Department, Desert Research Center, Cairo, Egypt, tahachemist2008@gmail.com Prof. Dr. Ali Gamal Ahmed Al-kaf, Sana'a university, Yemen, alialkaf21@gmail.com Similar Articles: ANTIDIABETIC AND ANTIHYPERLIPIDEMIC ACTIVITY OF DRACAENA CINNABARI BALF. RESIN ETHANOLIC EXTRACT OF SOQATRA ISLAND IN EXPERIMENTAL ANIMALS THE SCOPING REVIEW OF CHINESE AND WESTERN MEDICINE TREATMENT OF DIABETIC FOOT IN ASIA ANTIHYPERGLYCEMIC AND ANTI-OXIDANT POTENTIAL OF ETHANOL EXTRACT OF VITEX THYRSIFLORA LEAVES ON DIABETIC RATS EFFECTS OF EMODIN ON BLOOD GLUCOSE AND BODY WEIGHT IN TYPE 1 DIABETIC RATS

DIABETOGENIC EFFECT OF STATINS: MOLECULAR MECHANISMS

Statins, HMG CoA inhibitors, are potent hypolipidemic drugs.They are used for the prevention of cardiovascular diseases and some of the most commonly used drugs worldwide. Long term statin therapy can cause a modest increase in new-onset diabetes risk, and there is great interest in the mechanisms for this adverse effect. Main proposed mechanisms are increased insulin resistance and some defects in insulin secretion. Many factors can affect the risk including pre-existing diabetic risk, older age and potency of statin. But clearly, the benefits of these drugs in preventing cardiovascular disease outweigh the potential risk of diabetes.The aim of this review is to give underlying pathomechanisms and clinical relevance of diabetogenic effect of statins. Peer Review History: Received: 18 May 2021; Revised: 24 June; Accepted: 29 June, Available online: 15 July 2021 Academic Editor: Dr. Ali Abdullah Al-yahawi, Al-Razi university, Department of Pharmacy, Yemen, alyahawipharm@yahoo.com UJPR follows the most transparent and toughest ‘Advanced OPEN peer review’ system. The identity of the authors and, reviewers will be known to each other. This transparent process will help to eradicate any possible malicious/purposeful interference by any person (publishing staff, reviewer, editor, author, etc) during peer review. As a result of this unique system, all reviewers will get their due recognition and respect, once their names are published in the papers. We expect that, by publishing peer review reports with published papers, will be helpful to many authors for drafting their article according to the specifications. Auhors will remove any error of their article and they will improve their article(s) according to the previous reports displayed with published article(s). The main purpose of it is ‘to improve the quality of a candidate manuscript’. Our reviewers check the ‘strength and weakness of a manuscript honestly’. There will increase in the perfection, and transparency. Received file: Reviewer's Comments: Average Peer review marks at initial stage: 5.0/10 Average Peer review marks at publication stage: 7.5/10 Reviewer(s) detail: Dr. Salfarina Ramli, Department of Pharmacology and Pharmaceutical Chemistry, Faculty of Pharmacy, Universiti Teknologi MARA, 42300 Puncak Alam, Selangor, Malaysia. salfarina2892@uitm.edu.my Dr. George Zhu, Tehran University of Medical Sciences, Tehran, Iran, sansan4240732@163.com Similar Articles: EFFECTS OF EMODIN ON BLOOD GLUCOSE AND BODY WEIGHT IN TYPE 1 DIABETIC RATS ACORUS CALAMUS L ON TYPE 2 DIABETES MELLITUS MEDICATION

Optimization of Metformin in the GRADE Cohort: Effect on Glycemia and Body Weight.

We evaluated the effect of optimizing metformin dosing on glycemia and body weight in type 2 diabetes. This was a prespecified analysis of 6,823 participants in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE) taking metformin as the sole glucose-lowering drug who completed a 4- to 14-week (mean ± SD 7.9 ± 2.4) run-in in which metformin was adjusted to 2,000 mg/day or a maximally tolerated lower dose. Participants had type 2 diabetes for <10 years and an HbA1c ≥6.8% (51 mmol/mol) while taking ≥500 mg of metformin/day. Participants also received diet and exercise counseling. The primary outcome was the change in HbA1c during run-in. Adjusted for duration of run-in, the mean ± SD change in HbA1c was -0.65 ± 0.02% (-7.1 ± 0.2 mmol/mol) when the dose was increased by ≥1,000 mg/day, -0.48 ± 0.02% (-5.2 ± 0.2 mmol/mol) when the dose was unchanged, and -0.23 ± 0.07% (-2.5 ± 0.8 mmol/mol) when the dose was decreased (n = 2,169, 3,548, and 192, respectively). Higher HbA1c at entry predicted greater reduction in HbA1c (P < 0.001) in univariate and multivariate analyses. Weight loss adjusted for duration of run-in averaged 0.91 ± 0.05 kg in participants who increased metformin by ≥1,000 mg/day (n = 1,894). Optimizing metformin to 2,000 mg/day or a maximally tolerated lower dose combined with emphasis on medication adherence and lifestyle can improve glycemia in type 2 diabetes and HbA1c values ≥6.8% (51 mmol/mol). These findings may help guide efforts to optimize metformin therapy among persons with type 2 diabetes and suboptimal glycemic control.

Management of metabolic syndrome and reduction in body weight in type II diabetic mice by inhibiting glycosphingolipid synthesis

Metabolic syndrome is defined by hyperlipidemia and cardiovascular complications. We have examined whether inhibition of glycosphingolipid synthesis can interfere with metabolic syndrome in a male mouse model of type II diabetes (db/db). The db/db and control mice (C57/BL6) (n = 6) fed chow for 30 weeks received vehicle (5% Tween-80 in PBS; 100 μl), or a biopolymer-encapsulated D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol (BPD) glycosphingolipid synthesis inhibitor daily via oral gavage for 6 weeks. Echocardiography revealed increased Ao-IMT in db/db mice compared to control. However, BPD decreased Ao-IMT, monohexosylceramide and dihexosylceramide, LDL, triglycerides, glucose, and raised HDL levels in db/db mice. This was due to increased gene expression of HMG-CoA reductase, LDLr, SREBP2, and bile acids: Cy7-a hydroxylase, LXR and FXR, lipoprotein lipase, VLDL receptor and PPAR. Treatment also increased the expression of superoxide dismutase-II to reduce the pro-oxidant status in these mice. We observed that decreased cholesterol levels correlated with decreased cholesterol sensing proteins e.g. NPC1 gene/protein expression and mammalian target of rapamycin (mTORC-1) and reduced body weight. Thus, glycosphingolipid synthesis inhibition is a novel approach to manage metabolic syndrome and reduce body weight in diabetic mice and with potential applications in humans.

Evaluation of a small type body weight load reduction system by pneumatic muscle by muscle activity

Evaluation of a small type body weight load reduction system by pneumatic muscle by muscle activity

1652-P: The Association between Long-Term HbA1c Variability, Blood Pressure, Cholesterol, and Body Weight in Type 2 Diabetes: Subanalysis of ABC Study

Aim: Visit-to-visit variability (VVV) of HbA1c was reported to be the risk of cardiovascular disease (CVD) in patients with type 2 diabetes mellitus (T2DM). However, factors related to VVV of HbA1c remain unclear. This study is first examined relationship between VVV of HbA1c and various parameters including VVV of blood pressure (BP), low-density lipoprotein-cholesterol (LDL-C), and body mass index (BMI). Material and Methods: Analyzed were 4,678 patients with T2DM throughout Japan (38 hospitals). The inclusion criteria were patients whose HbA1c, BP, LDL-C, and BMI were measured 12 or more times during the 24-month period. VVV of HbA1c, BP, LDL-C, and BMI were evaluated using the coefficient of variation (CV). This study is sub-analysis of ABC trial (UMIN000034231). Results: Mean age of participants was 61.3 ± 9.4 years (mean ± SD) and HbA1c was 57.2 ± 13.5 mmol/mol (7.4 ± 1.2%). Table shows univariate correlate and multiple regression analysis of HbA1c CV. HbA1c CV was correlated with HbA1c baseline, SBP CV, LDL-C CV, and BMI CV. In the multiple regression analysis, HbA1c baseline, LDL-C, and BMI CV were the strongest predictors of HbA1c CV. Conclusion: VVV of HbA1c was strongly correlated with VVV of LDL-C and BMI, and HbA1c baseline in patients with T2DM. A large-scale clinical trial needs to be conducted to clarify factors affecting VVV of HbA1c. Disclosure S. Minato: None. D. Matsutani: None. Y. Tsujimoto: None. Y. Kayama: None. M. Sakamoto: None. M. Nishikawa: None. K. Utsunomiya: None.

USE OF SIBUTRAMIN IN PHARMACEUTICAL DRUGS AND ANOREXIC DIETARY SUPPLEMENTS (REVIEW)

Background. The most effective anorexic drugs on the pharmaceutical market are sibutramine. According to the standard scheme, sibutramine is similar to amphetamine. The active metabolites of sibutramine, formed in the process of its metabolism, have high pharmacological activity compared with the original substances, so the drug may be toxic to the body. Sibutramine is used in the complex treatment of obesity, when adjusting excess body weight in type II diabetes, and also used in polycystic ovary syndrome. The drug has many serious undesirable side effects, such as an increase in systolic and / or diastolic pressure and heart rate; headaches, insomnia, disorders of the gastrointestinal tract and can cause death. In many countries of the world a wide range of serious side effects has been banned. Text. A description of the drug sibutramine, its status on the pharmaceutical market of the Russian Federation and other countries of the world, an overview of possible methods for determining sibutramine in food supplements. Conclusion. Recently, information about the undeclared addition of sibutramine to the anorexigenic dietary supplement (dietary supplement) to increase their effectiveness has increasingly appeared. Therefore, it is necessary to develop methods for determining sibutramine in anorexic dietary supplements. In this regard, an analysis of the methods used for the quantitative determination of sibutramine. As a rule, spectral methods are used to determine the authenticity of a sibutramine substance. The most common and effective method for determining authenticity and quantitative analysis of sibutramine is the HPLC (high performance liquid chromatography) method using mass spectrometric and diode array detectors (DAD). At the moment, a method for determining sibutramine in the composition of multicomponent drugs and dietary supplements to food of anorexigenic action is being developed, which will contribute to the development of pharmacy.